Abstract
Genetically-targeted medications are emerging as important therapies for
lymphatic malformations (LMs) unresponsive to sirolimus. We describe two
patients with EML4::ALK positive LMs, one with Gorham Stout Disease and
one with a large genitourinary (GU) LM, who were successfully treated
with ALK inhibitors. This report adds ALK inhibitors to the growing
toolbox of molecularly-targeted therapies for LMs.